Generated by AI
Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and rare diseases, with a primary emphasis on thyroid eye disease. The company’s current pipeline centers on antibody-based programs designed to target validated disease pathways, including intravenous and subcutaneous candidates for thyroid eye disease and additional assets aimed at autoimmune conditions. Viridian Therapeutics also advances FcRn inhibitor programs, expanding its work across immunology-focused indications. The company operates in the biotechnology and specialty therapeutics market, where it contributes to the development of differentiated medicines for patients with serious conditions that have limited treatment options. Headquartered in Waltham, Massachusetts, Viridian Therapeutics combines antibody discovery and protein engineering to support its research, clinical development, and future commercialization efforts.
Website221 Crescent Street
Waltham, MA, 02453
United States
The latest articles about VRDN.
2026-11-13. The following slide deck was published by Viridian Therapeutics, Inc.
Summary of Aug 6's posts. Generated by AI.
Summary of Jun 29's posts. Generated by AI.
Summary of Jun 29's posts. Generated by AI.
Investors talking about VRDN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.